Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test
SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Helix, a leader in precision health, today announced a partnership with leading cancer diagnostics company Veracyte that will make it easier for urologists to add comprehensive germline testing for patients with high-risk localized and metastatic prostate cancer. Through this collaboration, Helix's whole-exome based hereditary cancer test will be available alongside Veracyte's Decipher® Prostate test, enabling a more complete view of each patient's cancer biology and inherited risk.
The partnership was also highlighted during Veracyte's earnings call, reinforcing the shared commitment to expanding access to clinically actionable genomic insights in prostate cancer care.
The National Comprehensive Cancer Network® (NCCN®) guidelines recommend germline genetic testing for patients with metastatic and high-risk localized prostate cancer. Germline findings can influence therapeutic decision-making, including the use of targeted therapies like PARP inhibitors. The integration of Helix's hereditary cancer test into the Decipher ordering workflow gives physicians a convenient way to access this important information and deliver more personalized care.
"Patients diagnosed with cancer deserve seamless access to genomic insights that can improve their care – not just in academic centers, but wherever they're treated," said James Lu, M.D., Ph.D., CEO and co-founder of Helix. "Through our work with Veracyte, we're helping expand access to both germline and transcriptomic insights in a single clinical workflow, so physicians can more easily align care decisions with the latest clinical guidelines."
Understanding a patient's inherited predisposition to cancer offers a number of benefits. It can inform treatment choices, identify risk for additional cancers, and provide actionable information to at-risk family members. When paired with pharmacogenomic (PGx) testing, providers can also better match treatments to each patient's genetic profile to improve safety and efficacy.
This collaboration is part of Helix's broader mission to make precision medicine more accessible and impactful for all patients. Helix currently runs the Helix Research Network®, the largest and fastest growing precision clinical research network in the world, where several of their partners have begun launching universal cancer screening programs for patients diagnosed with cancer. With its proprietary Exome+® assay and Sequence Once, Query Often® model, Helix delivers high-quality genomic insights at scale, enabling ongoing clinical value that may reduce the need for repeat testing.
To learn more about how Helix is advancing precision oncology, visit https://www.helix.com.
About Helix:
Helix is the leading population genomics and precision health organization. Helix enables health systems, life sciences companies and payers to accelerate the integration of genomic data into patient care and therapeutic development. Learn more at www.helix.com.
Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/helix-and-veracyte-partner-to-expand-access-to-clinically-actionable-genomic-insights-in-prostate-cancer-care-302523983.html
SOURCE Helix
